Table 5.
Combination therapy of NAA and DX in swiss (nu/nu) mice bearing human MX-1 mammary carcinoma xenograft
| Dose, mg/kg
|
Average tumor volume, mm3, mean ± SEM on day
|
Total no. of mice (n) | Mice died of toxicity | Mice tumor-free on day 49 | ||||
|---|---|---|---|---|---|---|---|---|
| DX* | NAA* | D12 | D17 | D22 | D27 | |||
| 0 | 0 | 47.7 ± 11.1 | 98.1 ± 28.6 | 200.7 ± 49.4 | 353.9 ± 63.3 | 7 | 0 | 0 |
| 1.5 | 32.3 ± 6.3 | 80.0 ± 29.2 | 145.7 ± 30.5 | 198.4 ± 57.6 | 8 | 2 | 0 | |
| 50 | 42.6 ± 12.1 | 140.6 ± 45.6 | 282.7 ± 86.1 | 465.5 ± 86.3 | 7 | 0 | 0 | |
| 1.5 | 50 | 39.5† ± 7.9 | 60.6† ± 16.0 | 97.9‡ ± 23.9 | 90.0‡ ± 19.7 | 8 | 1 | 2 |
MX-1 tumor tissue 50 μl/mouse was implanted s.c. on day 0. Treatment started on day 7, i.p., DX daily for 5 days; NAA twice daily for 5 days (at 15 min and 90 min after DX injection). Thus, nude mice were treated on days 6–10 and days 13–17.
*
Control group received the solvent vehicle DMSO, 40 μl/mouse.
†, not significant; ‡, P < 0.05 when compared with tumor volume treated with DX in the absence of NAA.